• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

In Spite Of Strong Growth to Date, Sales of Eloxatin for Colorectal Cancer Are Expected To Slow Down Significantly In the Coming Years As Generic Oxaliplatin Begins To Enter the EU Markets

Posted on: Wednesday, 15 November 2006, 06:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c45259) has announced the addition of Pipeline/Commercial Insight: Colorectal Cancer - Shaping the Future Dynamics of Colorectal Cancer Management to their offering.

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.

Scope of this title:

-- Overview of colorectal cancer including epidemiology forecasts and unmet needs in the disease

-- Clinical and commercial evaluation of key marketed and late-phase pipeline drugs for colorectal cancer

-- Sales forecasts for existing and Phase III developmental drugs for colorectal cancer to 2015 in the seven major markets

-- Key events and factors influencing the sales forecasts for colorectal cancer drugs to 2015 at country level

Highlights of this title:

Despite remaining the mainstay of colorectal cancer treatment, sales of cytotoxics are expected to be overtaken by those of molecular targeted therapies by 2008, caused by the genericization of Camptosar/Campto and Eloxatin, and the growth of Avastin and Vectibix.

In spite of strong growth to date, sales of Eloxatin are expected to slow down significantly in the coming years as generic oxaliplatin begins to enter the EU markets. However, continuing growth in the US market means that overall sales of the drug will not decline in the seven major markets until 2013 when the US patent expires.

There are few drugs currently in Phase III development for colorectal cancer despite the high unmet needs in the disease. Amgens Vectibix, approved in September 2006 remains the most promising and is likely to overtake Erbitux as the leading monoclonal antibody EGFR inhibitor for colorectal cancer.

Reasons to read your copy:

-- Understand patient segmentation relevant to marketed and pipeline colorectal cancer drugs

-- Assess current and future competitive dynamics of colorectal cancer to determine the future size and scope of the market

-- Identify licensing and lifecycle management opportunities in the colorectal cancer market based on company portfolio and market needs

Chapter Outline:

Chapter 1. Executive summary

Chapter 2. Patient potential

Chapter 3. Country market assessments

Chapter 4. R&D approach

Chapter 5. Marketed drug analysis & forecasts

Chapter 6. Pipeline analysis

Chapter 7. Late-stage pipeline drug analysis & forecasts

Chapter 8. Commercial impact & lifecycle management: case studies

Chapter 9. Appendix A

Chapter 10. Appendix B

List of Tables List of Figures

For more information visit http://www.researchandmarkets.com/reports/c45259.

Source: Datamonitor

Source: Business Wire

More News in this Category